Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
aforementioned, alleviate, analytical, appeal, authoritative, bRT, caption, captioned, Chancery, choice, complementary, cryopreserved, deprioritize, diagnostic, discouraging, dismissed, duty, enhance, enhanced, Errant, expedited, forum, furniture, goal, inapplicable, lab, leave, lessor, loan, lovotibeglogene, LVV, Meta, Motion, mutual, mutually, oligoclonality, par, PDUFA, Plaintiff, purpose, RBC, recast, recoverability, recurrence, rental, retrospectively, Rocco, Rock, role, San, shortage, sitting, stipulated, stipulation, storage, thereunder, toxicity, transfusion, tray, troubled, unspecified, unvested, usage, vintage, vivo, wound, writing
Removed:
ABECMA, accelerated, accounted, accrue, active, add, adult, agent, agreeing, Aid, analogy, analyze, analyzed, antibody, applying, arrange, arrangement, attributed, beneficial, Biden, bill, billing, blood, BMS, Breakthrough, Brexit, bribery, budgetary, callable, capitalization, capitalized, CAR, category, characterization, charged, clarification, clarify, clonal, comparable, confirm, confirmatory, conservative, consistently, constraint, Conversion, country, Coupled, creditable, customer, deductibility, defect, demonstrating, derivative, designated, detected, dilutive, discontinue, downturn, drastic, effort, eighteen, endorsement, endpoint, equally, estate, estimating, EU, evolved, exercisable, exploration, falling, Fast, fatal, FEFO, finalizing, foregoing, fourth, fundraising, GDPR, globin, half, hand, hematologic, historically, immune, immunomodulatory, impacting, improve, incentivize, inhibitor, international, interpret, irrespective, jointly, Juno, Kingdom, largely, licensee, lift, lisocabtagene, lodge, low, malignancy, maraleucel, marketability, medicinal, method, modification, monoclonal, myeloma, Nonrefundable, notification, obsolescence, optimization, outbreak, outlined, participant, passage, payload, payroll, percent, periodically, practice, Precision, predominance, predominant, predominantly, Pregenen, prioritization, processed, processing, profit, project, promised, proteasome, ranging, real, realizable, recognizing, recommendation, referred, reflective, refractory, Regeneron, regulated, relapsed, repayable, replace, reserving, resolved, room, satisfied, scenario, Seattle, secondary, selected, sheet, shelf, shortened, simplify, Simplifying, sooner, sourced, SPA, Squibb, stimulate, strain, strict, summarized, supervisory, Switzerland, TDT, terminating, territory, therefrom, timeline, tisagenlecleucel, Track, UK, unchanged, unconditional, unintended, unobservable, unrestricted, unsatisfied, untreated, utilized, variable, varying, Washington, whichever, worldwide, worth
Filing tables
Filing exhibits
Related press release
BLUE similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of bluebird bio, Inc. (the “Company”) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his or her knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 9, 2022 | By: | /s/ Andrew Obenshain | |||||||||
Andrew Obenshain President, Chief Executive Officer and Director (Principal Executive Officer and Duly Authorized Signer) |
Date: May 9, 2022 | By: | /s/ Jason Cole | |||||||||
Jason Cole Chief Strategy & Financial Officer (Principal Financial Officer, Principal Accounting Officer and Duly Authorized Signer) |